# UBT251 Injection Phase II Clinical Study (CKD)

> **NCT07134335** · PHASE2 · RECRUITING · sponsor: **The United Bio-Technology (Hengqin) Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Obesity &Amp; Overweight
- Chronic Kidney Disease

## Interventions

- **DRUG:** UBT251
- **DRUG:** UBT251
- **DRUG:** UBT251

## Key facts

- **NCT ID:** NCT07134335
- **Lead sponsor:** The United Bio-Technology (Hengqin) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2030-07-11
- **Final completion:** 2030-07-11
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07134335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07134335, "UBT251 Injection Phase II Clinical Study (CKD)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07134335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*